Showing results (681-690 of 726) with videos related to

Sort By:
Pageof 73
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2010
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancerA D Seidman, A Brufsky, R H Ansari, et al.
Cell Reports|October 13, 2021
PI3Kδ coordinates transcriptional, chromatin, and metabolic changes to promote effector CD8+ T cells at the expense of central memoryJennifer L Cannons, Alejandro V Villarino, Senta M Kapnick, et al.
Biorxiv : the Preprint Server for Biology|January 13, 2025
A PI3Kδ-Foxo1-FasL signaling amplification loop rewires CD4+ T helper cell signaling, differentiation and epigenetic remodelingDominic P Golec, Pedro Gazzinelli-Guimaraes, Daniel Chauss, et al.
Nature Immunology|June 19, 2019
Single-cell RNA-seq reveals TOX as a key regulator of CD8+ T cell persistence in chronic infectionChen Yao, Hong-Wei Sun, Neal E Lacey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast CancerIan Krop, Vandana Abramson, Marco Colleoni, et al.
Nature Communications|June 23, 2021
The role of chalcogen vacancies for atomic defect emission in MoS2Elmar Mitterreiter, Bruno Schuler, Ana Micevic, et al.
Nature Communications|July 2, 2025
Graphene-driven correlated electronic states in one dimensional defects within WS2Antonio Rossi, John C Thomas, Johannes T Küchle, et al.
Nature Immunology|August 22, 2018
Hyperactivated PI3Kδ promotes self and commensal reactivity at the expense of optimal humoral immunitySilvia Preite, Jennifer L Cannons, Andrea J Radtke, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 22, 2013
Myeloid growth factorsJeffrey Crawford, James Armitage, Lodovico Balducci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2013
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumabLee S Schwartzberg, Kurt W Tauer, Robert C Hermann, et al.
Pageof 73